Endocrine Journal
Online ISSN : 1348-4540
Print ISSN : 0918-8959
ORIGINALS
Effects and safety of 131I-metaiodobenzylguanidine (MIBG) radiotherapy in malignant neuroendocrine tumors: Results from a multicenter observational registry
Keiichiro YoshinagaNoboru OriuchiHiroshi WakabayashiYuuki TomiyamaMegumi JingujiTetsuya HiguchiDaiki KayanoMakoto FukuokaAnri InakiAyane TorataniShozo OkamotoTohru ShigaYoichi M. ItoMasatoyo NakajoMasayuki NakajoSeigo Kinuya
Author information
JOURNALS FREE ACCESS

2014 Volume 61 Issue 12 Pages 1171-1180

Details
Abstract

Effective treatments for malignant neuroendocrine tumors are under development. While iodine-131 metaiodobenzylguanidine (131I-MIBG) radiotherapy has been used in the treatment of malignant neuroendocrine tumors, there are few studies evaluating its therapeutic effects and safety in a multicenter cohort. In the current study, we sought to evaluate the effects and safety of 131I-MIBG therapy for conditions including malignant pheochromocytoma and paraganglioma within a multicenter cohort. Forty-eight malignant neuroendocrine tumors (37 pheochromocytoma and 11 paraganglioma) from four centers underwent clinical 131I-MIBG radiotherapy. The tumor responses were observed before and 3 to 6 months after the 131I-MIBG radiotherapy in accordance with RECIST criteria. We also evaluated the data for any adverse effects. The four centers performed a total of 87 131I-MIBG treatments on 48 patients between January 2000 and March 2009. Of the treatments, 65 were evaluable using RECIST criteria. One partial response (PR), 40 stable disease (SD), and 9 progressive disease (PD) in malignant pheochromocytoma were observed after each treatment. Fourteen SD and one PD-were observed in paraganglioma. Patients with normal hypertension (systolic blood pressure (BP) > 130 mmHg) showed significantly reduced systolic BP after the initial follow-up (n=10, 138.1±8.2 to 129.5±13.5 mmHg, P=0.03). In adult neuroendocrine tumors with a treatment-basis analysis, there were side effects following 41 treatments (47.1%) and most of them (90.2%) were minor. In this multicenter registry, PR or SD was achieved in 84.6% of the treatment occasions in adult neuroendocrine tumors through 131I-MIBG radiotherapy. This indicated that most of the 131I-MIBG radiotherapy was performed safely without significant side effects.

Information related to the author
© The Japan Endocrine Society
Previous article Next article
feedback
Top